Alliancebernstein L.P. Sells 173,955 Shares of Hologic, Inc. $HOLX

Key Points

• Alliancebernstein L.P. reduced its stake in Hologic, Inc. by 6.8%, owning 2,381,256 shares valued at $147.09 million as of its latest ETF filing.
• Several analysts raised their price targets for Hologic, with Royal Bank Of Canada upgrading its rating to "outperform" and setting a target price of $87.00.
• Hologic reported a 1.2% year-over-year revenue increase for the last quarter, with an EPS of $1.08, exceeding expectations set at $1.05.

Alliancebernstein L.P. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,381,256 shares of the medical equipment provider's stock after selling 173,955 shares during the quarter. Alliancebernstein L.P. owned approximately 1.07% of Hologic worth $147,090,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. EP Wealth Advisors LLC raised its stake in shares of Hologic by 8.4% during the 1st quarter. EP Wealth Advisors LLC now owns 9,828 shares of the medical equipment provider's stock worth $607,000 after purchasing an additional 760 shares in the last quarter. Alamea Verwaltungs GmbH acquired a new position in shares of Hologic during the 1st quarter worth about $702,000. Retirement Planning Co of New England Inc. bought a new stake in shares of Hologic in the first quarter valued at approximately $278,000. Quarry LP grew its position in Hologic by 89.9% in the 1st quarter. Quarry LP now owns 3,713 shares of the medical equipment provider's stock worth $229,000 after purchasing an additional 1,758 shares during the last quarter. Finally, Vident Advisory LLC increased its stake in Hologic by 256.6% during the first quarter. Vident Advisory LLC now owns 20,933 shares of the medical equipment provider's stock valued at $1,293,000 after acquiring an additional 15,063 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. UBS Group increased their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $78.00.

Hologic Trading Down 1.5%

NASDAQ HOLX traded down $0.98 during trading hours on Wednesday, hitting $65.75. The company's stock had a trading volume of 190,257 shares, compared to its average volume of 2,671,081. The stock has a fifty day moving average of $66.40 and a 200 day moving average of $62.63. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The firm has a market capitalization of $14.62 billion, a P/E ratio of 27.32, a PEG ratio of 2.42 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business posted $1.06 EPS. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.